Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hey thanks..where'd we meet b4?back in bugs or qsgi or...?
bmod! i dont recall!
Talk to me Goose, what do you have here? By the way, great seeing ya, its been awhile.
back to a penny,wish i'd got them 006's
tried calling for shares but ta wont give info and they didnt have #for the co.,told me to call john thomas legal to get #...he was at lunch so will try again.but vol is picking up and i cant get any 005's
DOMS on the bid attack. Its nice to see someone other than ETMM and NITE waking up in this stock. Need some volume here and it should be a good shell play at these levels and such a low share structure, don't you think Titun?
Thanks for your update Titun.. I had this on my watchlist and bought a starter position just to see how this will play out. I like the charts and that is my only basis for buying in.
FYI, check out NSMG.. No news and dilution and it had dropped to .002 but in a matter of a few months, was a 10 bagger if I had held on till then. This looks like the bottom for this stock and I feel that the share structure is appropriate for a nice run if anything positive ever came out of it. Even if it does not, I will only lose some profit money from some other play and so, its all good. :)
Godfather.. who are you kidding... this is nothing but an empty shell... Mr. Gardner has nothing going for the company... such as any idea as how to turn an honest profit...
Hell... my associate has tried to call him three to four times.. looking to discuss offering out cancer technology through his shell.... and with no success, because Chene is simply too afraid to pick up the phone or he is truing to hide from the FEDS...
Too bad too, because what we have is a patent pending method on how to increase the toxicity of chemo compounds up to ten times there normal toxicity while at the same time reducing the over all systemic toxicity by over 1000%. CTHP would be a perfect vehicle... less then 100,000,000 shares out standing... very low debt.. and no employees to have to contend with, other then our own people... CTHP would be a perfect host, and we weren't even considering having control, just control over our property... the patent-pending methodology.... Just to give you an idea as to how simple it is to turn a clean profit using our technology... the other company which is using the old version of our technology is generating well close to $2,000,000.00 a year with only a 15% operating overhead... and they are not using any drugs with the old method... our new method is 5 times more effective and just as practical... Chene and his cohorts are playing all of you for fools.... and I know the Godfather would never let any one make a fool out of him... so... what are you up to Godfather..
tell us.
Titon.
Bought some at .0075 today.. Lets see how she behaves in the coming days.. Looks tight!!
Close at .009 would look nice for the chart.
oo75 x 01 377k v...something could be brewing here,nite keeps moving to 011
wow...the bid has been moving up the past couple days. don't know if i should nibble here or not?
Wow BigLab.. your second link looks to be worth following up on...
I wouldn't mind swapping some of my technology for a few million shares of this stock.... Salt Lake City... its a small world after all......
Thanks.
Your Neighbour.
Rev.Lenard Snow.
God's Consignee
C/O
Titon.
Very interesting... sounds an awful lot like what I have described back in 2001..?.. I think.. maybe it was 2002...
It was discussed on the QLT board over at RB.... we were discussing possible delivery systems for their drug.. verteporfin
A close friend of mine had given the idea of adding colour to their benzoporphyrin so as to cause it to absorb more energy from red light sources...
Of course.. you all know that.. Lose lips give away the Billion Dollar Ideas... right..
Very interesting...... but stupid....NOT!!!!
Thanks.
Your Neighbour.
Rev.Lenard Snow.
God's Consignee.
C/O
Titon.
Holy cow...someone raised the bid...hey...it's going to .02 get on board!
Is that sincere enough pumping for you! Let's just say...Caveat Emptor!
Lies, lies and more lies.... Dr. Mark Kester has virtually nothing to do with CTHP and was never on the Board of Directors. They messed up big time. They are now called Cancer Cellular Therapeutics and I can't understand how they plan to make money with this change. The TA can't give the O/S and good luck getting a live person to comment on anything related to CancerTherapeutics Inc. Here is the number to your new investment 800 279-2796 and website http://cancercellulartherapeutics.com/ Was waiting to see if this would turn into something worth investing in and I certainly have come up with plenty of reasons not to at this point. Good luck, I'm done looking at this one.
Anyone get in touch with Integrity?
Previous post by reginoo and Jim Bishop btw.
Here's the best I can come up with:
Quote:
SHORTS data explained by FINRA...phone call 3 minutes ago i spoke to FINRA regarding their daily SHO list which seems to show 30-70 % off all the volume in thousands of stocks as 'short sales'. they explained the 2 factors which tend to inflate the short sale data beyond what is normally considered a short sale, i.e. a person or firm borrowing shares which are then sold.
1. all marketmaker sells to buyers for which the MM doesnt at that moment possess the stock would go onto the list. the shorts data is sent to SEC at time of execution, so during the course of a day, a MM may trade 20M shares of company xyz, of which 10M of those shares were initiated as short sales and the other 10M were buys to cover those shorts. despite the fact that their net position at the end of the day is flat, the data would show 10M shares as having been short sales.
this applies even to grey sheet stocks. despite the fact there is no MM making bids and asks, MM's can and do call around to other MM's to find willing sellers to match buy orders and vice-versa.
2. Trades in certain classes of
securities, such as Rule 144A securities, are
reported to the ORF, but not disseminated. Nondisseminated
securities will not be included in
either the daily short sale volume file or the
monthly short sale transaction file.
FINRA: they confirmed that in order to ascertain the true "open short" position one should look at the bi-monthly short report. it was also stated that any of the daily shorts which were not delivered within the prescribed time would definitely end up on the FTD list.
Oh. Makes sense. Why is it considered the RegSho data and why is this the system that tracks naked shorting?
I mean, I don't see anything about CTHP in that press release from Tesaro Inc.
If there was even a sniff of anything about CTHP in that PR (which there isn't) our price wouldn't be in the .008's right now, imo.
Again here is the full PR:
TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics and supportive care products. Participants in a $20 million Series A financing included New Enterprise Associates (NEA) and TESARO management; additionally, NEA has reserved $40 million to support company growth. The company is co-founded by former executives of MGI PHARMA, an oncology and acute-care focused specialty biopharmaceutical company that was acquired by Eisai Co., Ltd. in 2008 for $3.9 billion. The TESARO leadership team includes Lonnie Moulder, Chief Executive Officer; Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer; and Rick Rodgers, Executive Vice President and Chief Financial Officer. TESARO is dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics and supportive care agents.
"Cancer patients are in need of more effective and safer therapies, yet many promising drug candidates are currently under-resourced," said Lonnie Moulder, Chief Executive Officer. "The TESARO team will apply its demonstrated competencies to identify, acquire, develop and commercialize those potential drug candidates that will make a meaningful difference in the lives of cancer patients."
"Scientific advances are beginning to enable the simultaneous targeting of critical nodes in biochemical and metabolic pathways associated with cancer. In addition, co-development of drugs with correlative diagnostic tools will facilitate the targeting of the most appropriate patients," said Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer. "TESARO will take advantage of this progress as we develop drug candidates within defined populations, thereby imparting the greatest benefit to patients."
David M. Mott, General Partner at NEA, said, "Lonnie Moulder, Mary Lynne Hedley and Rick Rogers are the type of entrepreneurs NEA loves to back. This team has an exceptional track record for delivering value to all constituencies including patients, investors and employees, and importantly, they have previously worked together as a team. Oncology therapeutics is among the largest and fastest growing segments of the biopharmaceutical industry, yet cancer patients remain among the most underserved by today's drugs. We believe there is a tremendous opportunity for the TESARO team to make a real difference for cancer patients while delivering value for their investors and employees."
ctenewman that is probably the most misunderstood
and abused data on IHUB. Here is the correct explanation.
Posted by: overachiever Member Level Date: Friday, February 19, 2010 2:00:24 PM
In reply to: southernnoise who wrote msg# 296116 Post # of 296144
Unless you know what you are looking at, you shouldn't draw any false conclusions. Those are daily tracking numbers
Until a security is delivered, it is considered to be technically short.
If I sell some SPNG today, it will show up as a short sale on FINRA records until my MM meets the buying MM "at the window". This can take up to 10 days. All you are really looking at is the sell side volume minus any flips or buy side through the same dealer. For example. If I buy 10 shares and you sell 20 shares and we are both using NITE and this is the only volume they handled all day long, the system would show NITE is short 10 shares until they deliver your stock to the buyer. Understand?
Stock is never delivered the same day you sell it. That would not be possible.
OK, here is the full press release, which doesn't mention Cancer Therapeutics Inc (the company CTHP) anywhere. It only uses the words "cancer therapeutics" as something Tesaro Inc works on.
http://www.marketwatch.com/story/tesaro-inc-secures-60-million-in-start-up-funding-2010-05-26?reflink=MW_news_stmp
Did you buy the full report for $10 ? Kinda wonder what it says inside and who their sources are
ETMM kinda freaking me out on the bid now. Grrrr. Get away from there!
sorry I "spammed"... but the short volume is ridiculous on this stock. Over 50 percent short volume in the last 5 days.
Obviously, from the link I found, something is in the works that hasn't been released yet.
maybe the TA started their holiday weekend early
I know I'm trying too, but haven't got through. Just left a message.
Don't want to hold if there is still active diluting, and that's what the pattern has looked like lately. All trades at ask...ask is dropped by mysterious non-MM seller to .0094 , more trades at the ask, then a sudden drop of bid / ask into the .008's
That kind of stuff happens when more shares are sold into the pool-- the value of existing shares drops, even if there was buying at higher prices only seconds earlier. That's when alarms go off in my brain :-P
So, I'm watching. Once NITE and ETMM are out of the way, then maybe we'll see if "somebody" is still sitting at .0094
You can watch it here for kicks:
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=CTHP
Don't sell buddy!!
Silence Therapeutics receives US patent for RNAi cancer therapeutics
Sorry may be wrong Co. Please Delete
http://www.tradingmarkets.com/news/stock-alert/slncf_silence-therapeutics-receives-us-patent-for-rnai-cancer-therapeutics-953838.html
well, if Integrity would answer the phone,I'd tell ya
What is it as of...um...May 28th?
Just wondering. Note, April 7th is before the tanking of the stock price began-- everything was "normal" then.
Just called the T/A number and got a recording. They close early on Friday (of course). Left a message with my question and my phone number. I'll see what happens. Maybe I'll be out of this stock by Monday though. Depends on my mood EOD :-P
no, just caught ctnewman's spam, that's all
Thanks PF... you in here?? bbilly
Im having the same issue...bbilly
I got out at 0.059-0.061 got a few at 0.01
As far as the DD someone did, they said the company was doing things, call the company about the public stock, you may find a different story from them.
As far as a pr, do not think that is something you will see anytime in the near future.
Integrity Stock Transfer 1-702-317-7757, O/S was 85 mil as of April 7th
I was told they were empty, obviously that is not the case, sorry, I just posted what I knew at the time.
one thing all traders here know, the current level is not a level that anyone can profit at, so that being said, the only ones that can sell down here are the 2 that have shares that did not cost them what others paid.
I'm pretty sure the T/A contact info is on the "investors" link on the company website here:
http://www.cancer-therapeutics.com
But for some reason their homepage isn't loading right now. Keeps "timing out" on my end. Can anybody else get there at the moment?
Is there a T/A we can get ahold of to find out if the OS has gone up?? bbilly
These two links together should explain a lot.
http://www.azonano.com/news.asp?newsID=17692
http://www.wikinvest.com/stock/Cancer_Therapeutics_Inc._(CTHP)
My guess is that the stock price has been held and forced down intentionally so certain parties can load up. Might get one of those third party promos on this soon if my theory holds true.
Check out this link...
http://www.alacrastore.com/storecontent/newstex/BW-0001-45437063
Somebody keeps holding the ask down...not an MM. This morning it was at .0094 while all the MM's had their ask set above that. At this price, the only "seller" I can imagine is the company selling more shares into the pool. They are the only "seller" that wouldn't be selling for a loss at that price. And that explains the sudden MM jump to .008 x .009 even after buys at the .0094 (more shares means less value per share).
Anyway...just my 2 cents (which will be 1 cent soon if this continues).
Obviously someone is not done selling!.....your right. So, I'll just remain a spectator for the time being, and watch very closely - but, I'm still interested. :)
Very nice find! Notice this part?
Dr. Kester is the inventor of the C6-ceramide nanoliposome, which is being licensed through Penn State Research Foundation.
Over 60 percent of volume yesterday was short volume. The last 5 days, over 50 percent of volume is short. This thing is ready to bounce hard.
And I think TIFF has said that the sellers are done! Obviously someone is not done selling!
no I didn't... thanks!
Check out the link I posted. This should pop-up big after this is released in a PR. Look at all the institutions working to get CTHP/Dr. Kester invention to market. Looks like we caught the bottom on this. Time will tell, but I like how this is story is starting to unfold.
Could this send it screaming back to $1.00?
http://www.azonano.com/news.asp?newsID=17692
Notice Dr. Mark Kester. CTHP made an acquisition that puts us in the market with this C6-ceramide nanoliposome. And Dr. Mark Kester is on our board.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
324
|
Created
|
06/09/09
|
Type
|
Free
|
Moderators |
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
CTI’s first investment under this strategy is NanoTherapies LLC. Nano’s products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles. These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells. The compatibility of the calcium phosphate nanoparticle with the biomechanics of the human body makes it unique for application in the treatment of diseases. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense.
The development of these life-changing therapies for cancer treatment is achieved through an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). Nano also owns all rights to manufacturing technologies and patents required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Four drugs have been identified for accelerated market delivery and early revenue: Methotrexate, Cytarabine, Fludarabine and Daunorubicin. Cerimide-based drugs and a newly discovered Amplified Photon Emission Therapy (APET) also comprise part of the product portfolio, but will require longer clinical trials to get to market.
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
CTI’s first investment under this strategy is NanoTherapies LLC. Nano’s products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles. These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells. The compatibility of the calcium phosphate nanoparticle with the biomechanics of the human body makes it unique for application in the treatment of diseases. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense.
The development of these life-changing therapies for cancer treatment is achieved through an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). Nano also owns all rights to manufacturing technologies and patents required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Four drugs have been identified for accelerated market delivery and early revenue: Methotrexate, Cytarabine, Fludarabine and Daunorubicin. Cerimide-based drugs and a newly discovered Amplified Photon Emission Therapy (APET) also comprise part of the product portfolio, but will require longer clinical trials to get to market.
Cancer Therapeutics will be in a position to engage high level personnel and intellectual capital from NanoTherapies to evaluate other synergistic investment opportunities. CTI will then pursue the most promising and valuable technologies to reach the market expeditiously and benefit the lives of cancer patients worldwide.
Cancer Therapeutics Inc is a Delaware corporation. CTI’s Common Stock is listed on the NASD Electronic Bulletin Board under the symbol “CTHP.” The Company’s stock has been traded on the Bulletin Board since March, 2007.
Cancer Therapeutics Inc is located in South Jordan (Salt Lake City), Utah.
Cancer Therapeutics Inc
10757 S. River Front Pkwy.
Suite 125
South Jordan, Utah 84095
Telephone (801) 816-2533
Facsimile (801) 816-2599
Email
Chene Gardner
President, Chief Executive Officer, Chief Financial Officer
John D. Thomas
General Counsel
Outstanding Shares: 85,541,266 as of Sep 07, 2010
The information contained within this iBox including web links, copied information, and any other associated messages/media (hereinafter collectively referred to as "Information") is provided for informational purposes only. The Information should not be construed as investment/trading advice and is not meant to be a solicitation or recommendation to buy, sell, or hold Cancer Therapeutics, Inc. (CTHP) stock.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |